This Week We Added 70 Companies and 120+ Funding Events

CipherBio Weekly Digest: Week of Feb 3 – Feb 9, 2022

This week’s we bring you news and events about $2.77B in deals, $391.90M in Series A, 70 companies and 29 investors added to our CipherBio platform.

$2.77B
Deals

$391.90M
Series A 

$324.2M
Series B 

$506.3M
Later Rounds 

$1.2B
M&A/IPOs 

70
New Companies on CipherBio

Sign Up For Your Free Account ➜

 

Top Deals This Week

Seismic Therapeutic raises $101M in Series A round led by Lightspeed Venture Partners. Endeavor BioMedicines raises $101M in Series B led by Ally Bridge Group and Avidity Partners. Also in Series B  ConcertoCare raises $105M led by Wells Fargo Strategic Capital. Dewpoint Therapeutics gets $150M in Series C led by Softbank Vision Fund 2. Ventus Therapeutics raises $140M / Series B led by Softbank Vision Fund 2 and RA Capital Management. In Series F Lyra Health raises $235M led by Dragoneer Investment Group.

See Investors Insights ➜
Company Round Amount
Seismic Therapeutic Series A $101M
Endeavor BioMedicines Series B $101M
ConcertoCare Series B $105M
Dewpoint Therapeutics Series C $150M
Ventus Therapeutics Series C $140M
Lyra Health Series F $235M

 

 

This Week’s Lead Investors in Top Rounds

Lead investors this week are Lightspeed Venture Partners, Ally Bridge Group, Avidity Partners, Wells Fargo Strategic Capital, Softbank Vision Fund 2, RA Capital Management, Dragoneer Investment Group.

  Profile Picture

See Investors Insights ➜

 

 

This Week in Clinical Phases

In phase 1 Synthekine announces trial of STK-012 for the treatment of solid tumors. Also, Avacta Group announces a phase 1 trial of their product AVA6000. French-based ImCheck Therapeutics starts phase 2 trial of their anti-BTN3A  monoclonal antibody ICT01. Acurx Pharmaceuticals starts their phase 2A trial of Ibezapolstat, their lead antibiotic candidate. Nanoscope Therapeutics starts a phase 2B trial of MCO-010 for gene therapy to restore vision. SaNOtize starts phase 3 trial of Nitric Oxide Nasal Spray (NONS) as an effective COVID-19 treatment. BioCardia receives FDA Breakthrough Device for the CardiAMP cell therapy system.

See All Clinical Insights ➜
Company Product and Clinical Phase Indications
Synthekine STK-012Phase 1 Oncology, Solid Tumors, Cancers and Other Neoplasms (NOS)
Avacta Group AVA6000, Phase 1 Oncology, Cancers and Other Neoplasms (NOS)
ImCheck Therapeutics ICT01, Phase 2 Melanoma, Cancers and Other Neoplasms (NOS), Gastric Cancer, Breast Cancer, Lymphoma, Prostate Cancer
Acurx Pharmaceuticals Ibezapolstat, Phase 2A Clostridium Difficile Infections (CDI), Bacterial Infections, Infections
Nanoscope Therapeutics MCO-010, Phase 2B Retinal Diseases, Orphan/Rare Diseases, Retinitis Pigmentosa, Eye Diseases, Gene Therapy
SaNOtize Nitric Oxide Nasal Spray (NONS), Phase 3 COVID-19
BioCardia CardiAMP, FDA Breakthrough Device Heart Failure, Cardiovascular Health, Cell Therapy

Starfield, food & science technology, raised $100M in Series B round led by Primavera Capital Group, Lightspeed China Partners and Joy Capital. FlipDish raised $100M in Series C led by Tencent. In AgTech MycoWorks raised $125M in Series C to build a new alt-leather factory. WayCool raised $117M in Series D led by LightRock, LightBox, FMO and others.

 

 

70 Life Science Companies Added

This week we added 123 funding events, 70 life science companies and 29 investors.

 

15 of 70 Companies
See Companies Insights ➜
Resonant Link Timber Pharmaceuticals ConcertoCare
Waterdrop Zero Acre Farms Retailo
Vena Medical Nemis Technologies Lover
Rose Health Penrod DAMAE Medical
GreenLight Biosciences Azooka Labs Perfuze

 

To get all the latest life science deals and VC funding data delivered straight to your inbox weekly become a CipherBio PRO member.

Get CipherBio PRO Account

Request Your PRO Demo